Cannabidiol/hydroxychloroquine - Incannex
Alternative Names: IHL-675; IHL-675ALatest Information Update: 07 May 2024
At a glance
- Originator Incannex Healthcare
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antimalarials; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Antivirals; Anxiolytics; Cannabinoids; Cardiovascular therapies; Chlorobenzenes; Cyclohexenes; Disease-modifying antirheumatics; Drug withdrawal therapies; Ethanolamines; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Quinolines; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Autophagy inhibitors; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Cytokine inhibitors; Phospholipase A2 inhibitors; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 07 May 2024 Phase-II clinical trials in Adult respiratory distress syndrome (unspecified route) (Incannex Healthcare pipeline; May 2024)
- 07 May 2024 Phase-II clinical trials in Asthma (unspecified route) (Incannex Healthcare pipeline; May 2024)
- 07 May 2024 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route) (Incannex Healthcare pipeline; May 2024)